LeMaitre Vascular Dividend and Recent Developments: Insights Ahead of Ex-Dividend Date Aug 21, 2025
Generated by AI AgentAinvest Dividend Digest
Sunday, Aug 17, 2025 7:04 pm ET1min read
LMAT--
Aime Summary
Aime SummaryLeMaitre Vascular (LMAT) has announced a dividend of $0.200 per share, with an ex-dividend date set for Aug 21, 2025, and payment scheduled for Sep 4, 2025. This figure is significantly higher than the average of the last ten dividends, which stood at approximately $0.078 per share. The dividend type, translated from Chinese, is a cash dividend. The company last distributed dividends on May 29, 2025, maintaining the same per-share payout and dividend type.
Recently, LeMaitre VascularLMAT-- has seen notable transactions and updates that could influence its market performance. Director Lawrence Jasinski sold 976 shares at $92.78 each on Aug 12, 2025, a transaction valued at $90,553. This move highlights insider trading activity, which might affect investor sentiment.
Over the past week, LeMaitre Vascular reported second-quarter earnings, revealing a 15% revenue growth to $64.230 million and a gross margin of 70%, driven by international expansion and a premium product mix. The EMEA region registered a 23% sales growth, with the APAC region following with a 12% increase, fueled by demand for vascular care and new product approvals. Analysts project 2025 revenue of $251 million and an EPS of $2.30, reflecting confidence in the company's scalable global model.
As of late, Cetera Investment Advisers acquired 5,769 shares, indicative of growing interest in LMAT’s stock. Furthermore, LMATLMAT-- has been upgraded to 'Outperform' by analysts, reinforcing its position as a strong player in the medical device industry, known for its commitment to innovation and operational discipline.
In conclusion, LeMaitre Vascular is positioned as a compelling investment opportunity with its strategic expansions and promising financial health. Investors should note that Aug 21, 2025, is the last day to purchase LMAT shares to be eligible for the upcoming dividend. Any acquisitions made after this date will not qualify for this dividend distribution.
Recently, LeMaitre VascularLMAT-- has seen notable transactions and updates that could influence its market performance. Director Lawrence Jasinski sold 976 shares at $92.78 each on Aug 12, 2025, a transaction valued at $90,553. This move highlights insider trading activity, which might affect investor sentiment.
Over the past week, LeMaitre Vascular reported second-quarter earnings, revealing a 15% revenue growth to $64.230 million and a gross margin of 70%, driven by international expansion and a premium product mix. The EMEA region registered a 23% sales growth, with the APAC region following with a 12% increase, fueled by demand for vascular care and new product approvals. Analysts project 2025 revenue of $251 million and an EPS of $2.30, reflecting confidence in the company's scalable global model.
As of late, Cetera Investment Advisers acquired 5,769 shares, indicative of growing interest in LMAT’s stock. Furthermore, LMATLMAT-- has been upgraded to 'Outperform' by analysts, reinforcing its position as a strong player in the medical device industry, known for its commitment to innovation and operational discipline.
In conclusion, LeMaitre Vascular is positioned as a compelling investment opportunity with its strategic expansions and promising financial health. Investors should note that Aug 21, 2025, is the last day to purchase LMAT shares to be eligible for the upcoming dividend. Any acquisitions made after this date will not qualify for this dividend distribution.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet